Learn about multiple myeloma treatment options available for patients from Bristol Myers Squibb®. Please see Indication and Important Safety Information including Boxed WARNINGS.
Learn about multiple myeloma treatment options available for patients from Bristol Myers Squibb®. Please see Indication and Important Safety Information including Boxed WARNINGS.
EP: 6.Educating Patients on Treatment Options for Multiple Myeloma EP: 7.Multiple Myeloma: Regulatory Aspects of Treatment Development and Approval EP: 8.Importance of Clinical Trial Enrollment in Multiple Myeloma EP: 9.Impact of Clinical Trials on the Management of Multiple Myeloma EP: 10.Ho...
EP: 4.First-Line Treatment Options for Transplant-Ineligible NDMM: Focus on MAIA Trial EP: 5.Outcomes with Daratumumab in Frontline Versus Subsequent Lines of Therapy in Transplant-Ineligible MM EP: 6.Novel BCMA-Targeting Agents for the Treatment of Relapsed/Refractory Multiple Myeloma ...
The multiple myeloma condition center is a comprehensive resource for clinical news and expert insights on multiple myeloma. Read more at OncLive.
Wislùff F, Gulbrandsen N, Nord E (1999) Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations. Pharmacoeconomics 16 : 329-341.Wisloff F,Gulbrandsen N,Nord E.Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and qual...
Multiple myeloma (MM) is a malignant plasma cell disease in which tumor cells originate from plasma cells in the bone marrow, and plasma cells are cells that develop to the final stage of function of B lymphocytes. Therefore, multiple myeloma can be classified as B lymphocyte lymphoma. The WH...
treatment-naiveEstablished treatments for transplant-ineligible (TNE) patients with newly diagnosed multiple myeloma (NDMM) include melphalan and prednisone (MP) combined with either bortezomib (VMP) or thalidomide (MPT), or lenalidomide plus low-dose dexamethasone (Rd). New treatments for TNE NDMM ...
Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM).
The treatment of relapsed multiple myeloma remains a challenge for clinicians. Most salvage therapies result in transient responses, with median survival from relapseranging from 6 to 18 months. No randomized trials comparing salvage therapies have been performed. In the absence of a “gold standard”...